SGLT‐2 inhibitors also significantly decreased the risk of depression (AOR: 0.09; 95% CI: 0.01‐0.63; P = .0153), but the number of T2DM patients with depression who had taken SGLT‐2 inhibitors was very small (n = 1 in Table 1). Here, SLC5A2 is linked to depressive disorder.